Supplementary materials: Cost–effectiveness analysis of prolonged-release fampridine to treat walking disability of multiple sclerosis in China

These are peer-reviewed supplementary materials for the article 'Cost–effectiveness analysis of prolonged-release fampridine to treat walking disability of multiple sclerosis in China' published in the Journal of Comparative Effectiveness Research.Symptomatic medications and duration of treatment in multiple sclerosis (MS) adult patients with walking disability (EDSS [expanded disability status scale] score 4-7)Frequency and duration of rehabilitation therapy in MS adult patients with walking disability (EDSS score 4-7)Healthcare resource utilization in the treatment of MS adult patients with walking disability (EDSS score 4-7)The relationship between walking ability and costsSupplementary Table 1 EQ-5D-5L utilities from the ENHANCE and MOBILE trialObjectives: This study evaluates the cost–effectiveness of adding prolonged-release (PR)-fampridine to best supportive care (BSC) versus BSC alone in adult multiple sclerosis patients with walking disability in China. Materials & methods: A hybrid decision tree and Markov model from both the societal and healthcare perspectives were constructed. Parameters were derived from clinical trials of PR-fampridine, published sources and clinical expert interviews. Results: Over a 10-year time horizon, adding PRfampridine to BSC led to 0.15 quality-adjusted life year (QALY) gain and lower costs,with incremental cost–effectiveness ratios of -238,806 Chinese Yuan/QALY and -113,488 Chinese Yuan/QALY from the societal and healthcare perspectives, respectively. Conclusion: Compared with BSC alone, PR-fampridine plus BSC is considered an economically dominant strategy for the treatment of multiple sclerosis-related walking disability in China.